|  Help  |  About  |  Contact Us

Publication : Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury.

First Author  Kirkby NS Year  2012
Journal  Cardiovasc Res Volume  95
Issue  1 Pages  19-28
PubMed ID  22467315 Mgi Jnum  J:202580
Mgi Id  MGI:5520037 Doi  10.1093/cvr/cvs137
Citation  Kirkby NS, et al. (2012) Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury. Cardiovasc Res 95(1):19-28
abstractText  AIMS: The potent vasoconstrictor endothelin-1 (ET-1), acting on the endothelin-A (ETA) receptor, promotes intimal lesion formation following vascular injury. The endothelin-B (ETB) receptor, which mediates nitric oxide release and ET-1 clearance in endothelial cells, may moderate lesion formation, but this is less clear. We used selective ET receptor antagonists and cell-specific deletion to address the hypothesis that ETB receptors in the endothelium inhibit lesion formation following arterial injury. METHODS AND RESULTS: Neointimal proliferation was induced by wire or ligation injury to the femoral artery in mice treated with selective ETA (ABT-627) and/or ETB antagonists (A192621). Measurement of lesion formation by optical projection tomography and histology indicated that ETA blockade reduced lesion burden in both models. Although ETB blockade had little effect on ligation injury-induced lesion formation, after wire injury, blockade of the ETB receptor increased lesion burden (184% of vehicle; P < 0.05) and reversed the protective effects of an ETA antagonist. Selective deletion of ETB receptors from the endothelium, however, had no effect on neointimal lesion size. CONCLUSION: These results are consistent with ETB receptor activation playing an important role in limiting neointimal lesion formation following acute vascular injury, but indicate that this protective effect is not mediated by those ETB receptors expressed by endothelial cells. These data support the proposal that selective ETA antagonists may be preferable to mixed ETA/ETB antagonists for targeting the arterial response to injury.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

7 Bio Entities

0 Expression